Long

$GENE Bullish reversal in Genetic Tech

193
Genetic Technologies Ltd. engages in the provision of molecular risk assessment for cancer. It operates through the USA and Australia geographical segments. Its product, BREVAGenplus, is a clinically validated risk assessment test for non-hereditary breast cancer. The company was founded on January 5, 1987 and is headquartered in Fitzroy, Australia.

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.